PMID- 14752069
OWN - NLM
STAT- MEDLINE
DCOM- 20040224
LR  - 20151119
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 22
IP  - 3
DP  - 2004 Feb 1
TI  - Effect of duration of treatment on treatment outcome for patients with clear-cell 
      sarcoma of the kidney: a report from the National Wilms' Tumor Study Group.
PG  - 468-73
AB  - PURPOSE: To evaluate the effect of conventional and standard (ST) versus 
      pulse-intensive (PI) chemotherapy and short-duration versus long-duration 
      chemotherapy on relapse-free survival (RFS) and overall survival rates of 
      patients with clear-cell sarcoma of the kidney (CCSK) entered onto the National 
      Wilms' Tumor Study (NWTS)-4. PATIENTS AND METHODS: The 5-year and 8-year RFS 
      rates were determined for patients with CCSK treated on the NWTS-4. After August 
      6, 1986, 40 previously untreated children younger than 16 years with CCSK were 
      randomly assigned, after the completion of 6 months of chemotherapy, to 
      discontinue (short) or continue 9 additional months (long) of treatment with 
      chemotherapy regimens that included vincristine and either divided-dose (ST) 
      courses (5 days) or single-dose (PI) treatment with dactinomycin and divided-dose 
      (ST) courses (3 days) or single-dose (PI) treatment with doxorubicin. RESULTS: 
      For patients with CCSK, the 5- and 8-year RFS rates were 65.2% and 60.6%, 
      respectively, for patients randomly assigned to the short chemotherapy and 87.8% 
      (both 5- and 8-year RFS) for patients randomly assigned to the long chemotherapy 
      (P =.08). The overall survival rates for patients at 5 and 8 years were 95.5% and 
      85.9%, respectively, for the short chemotherapy and 87.5% (both 5- and 8-year 
      overall survival) for the long chemotherapy (P =.99). In NWTS-4, the overall 
      survival rates for patients with CCSK improved from NWTS-3 (83% v 66.9% at 8 
      years, respectively; P <.01). CONCLUSION: CCSK patients exhibit an improved RFS 
      from a longer course of therapy when using vincristine, doxorubicin, and 
      dactinomycin, but their long-term survival is unchanged compared with patients 
      receiving 6 months of therapy. The overall survival rates for patients with CCSK 
      have improved from NWTS-3.
FAU - Seibel, Nita L
AU  - Seibel NL
AD  - Department of Hematology/Oncology, Children's National Medical Center, 111 
      Michigan Avenue NW, Washington, DC 20010, USA. nseibel@cnmc.org
FAU - Li, Sierra
AU  - Li S
FAU - Breslow, Norman E
AU  - Breslow NE
FAU - Beckwith, J Bruce
AU  - Beckwith JB
FAU - Green, Daniel M
AU  - Green DM
FAU - Haase, Gerald M
AU  - Haase GM
FAU - Ritchey, Michael L
AU  - Ritchey ML
FAU - Thomas, Patrick R M
AU  - Thomas PR
FAU - Grundy, Paul E
AU  - Grundy PE
FAU - Finklestein, Jerry Z
AU  - Finklestein JZ
FAU - Kim, Tae
AU  - Kim T
FAU - Shochat, Stephen J
AU  - Shochat SJ
FAU - Kelalis, Panayotis P
AU  - Kelalis PP
FAU - D'Angio, Giulio J
AU  - D'Angio GJ
LA  - eng
GR  - CA 42326/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 1CC1JFE158 (Dactinomycin)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Dactinomycin/administration & dosage
MH  - Disease-Free Survival
MH  - Doxorubicin/administration & dosage
MH  - Female
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Kidney Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*prevention & control
MH  - Neoplasm Staging
MH  - Sarcoma, Clear Cell/*drug therapy/mortality/pathology
MH  - Survival Rate
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage
EDAT- 2004/01/31 05:00
MHDA- 2004/02/26 05:00
CRDT- 2004/01/31 05:00
PHST- 2004/01/31 05:00 [pubmed]
PHST- 2004/02/26 05:00 [medline]
PHST- 2004/01/31 05:00 [entrez]
AID - JCO.2004.06.058 [pii]
AID - 10.1200/JCO.2004.06.058 [doi]
PST - ppublish
SO  - J Clin Oncol. 2004 Feb 1;22(3):468-73. doi: 10.1200/JCO.2004.06.058.